# Liraglutide Actions on the Liver: Effects on Glucose Phosphorylation

> **NCT02198209** · PHASE4 · WITHDRAWN · sponsor: **Cedars-Sinai Medical Center**

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Liraglutide

## Key facts

- **NCT ID:** NCT02198209
- **Lead sponsor:** Cedars-Sinai Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-12
- **Primary completion:** 2020-07
- **Final completion:** 2020-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Investigator decided not to move forward with study prior to study start date
- **Last updated:** 2019-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02198209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02198209, "Liraglutide Actions on the Liver: Effects on Glucose Phosphorylation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02198209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*